Meridian Signs Agreement in Principle to Acquire Line of Recombinant Proteins from Vybion, Inc.

finanznachrichten.de     May 13, 2008            

Meridian Bioscience, Inc. Cincinnati, Ohio (NASDAQ: VIVO) today announced it has executed a letter of intent to acquire a line of infectious disease recombinant proteins and cardiac antigens from Vybion, Inc. The purchase price includes cash and future royalties based on net sales of the acquired... [read full story]                    


*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies